Skip to content
TearSolutions: Naturally Treating Dry Eye (225) episode artwork

Jul 4, 2022 23 min

TearSolutions: Naturally Treating Dry Eye (225)

from Innovation4Alpha Hosted by Innovation4Alpha

TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B). The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

TearSolutions: Naturally Treating Dry Eye (225)

0:00 23:20

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Innovation4Alpha?

This episode is 23 minutes long.

When was this Innovation4Alpha episode published?

This episode was published on July 4, 2022.

Can I download this Innovation4Alpha episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.